FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

Noboru Nakaigawa,Keiichi Kondo,Tomohiro Kaneta,Ukihide Tateishi,Ryogo Minamimoto,Kazuhiro Namura,Daiki Ueno,Kazuki Kobayashi,Takeshi Kishida,Ichiro Ikeda,Hisashi Hasumi,Kazuhide Makiyama,Narihiko Hayashi,Kimito Osaka,Kentaro Muraoka,Koji Izumi,Takashi Kawahara,Jun-ichi Teranishi,Yasuhide Miyoshi,Yasushi Yumura,Hiroji Uemura,Tomio Inoue,Masahiro Yao

FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

2018

Purpose We investigated prospectively whether 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies.

Keywords:

Targeted therapy
Positron emission tomography
Radiology
Computed tomography
Pharmacology
PET-CT
Renal cell carcinoma
Molecular Targeted Therapies
Medicine
Urology
Standardized uptake value
Sorafenib
Temsirolimus
Imaging biomarker
Sunitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations